Toffart, Anne-Claire http://orcid.org/0000-0003-4377-0227
Meert, Anne-Pascale
Wallet, Florent
Gibelin, Aude
Guisset, Olivier
Gonzalez, Frédéric
Seguin, Amélie
Kouatchet, Achille
Delaunay, Myriam
Debieuvre, Didier
Duchemann, Boris
Rousseau-Bussac, Gaëlle
Nyunga, Martine
Grimaldi, David
Levrat, Albrice
Azoulay, Elie
Lemiale, Virginie
Funding for this research was provided by:
Roche
Article History
Received: 10 October 2022
Accepted: 24 March 2023
First Online: 18 April 2023
Declarations
:
: Study protocol has been approved by the Ethics Committee of the Jules Bordet Institute, Belgium (08/29/2018). According to French Law, there is an institutional review board waiver for this kind of research. Nonetheless, all patients had to sign an informed consent.
: Not applicable.
: ACT, grants and personal fees from AstraZeneca, personal fees and non-financial support from Bristol-Myers-Squibb, personal fees and non-financial support from MSD, grants, personal fees and non-financial support from Roche. APM, grants from Bristol-Myers-Squibb. FW, personal fees from Gilead kite, Novartis, Jazz pharmaceutical. BD, personal fees and non-financial support from AstraZeneca, personal fees from Roche. GRB, personal fees and non-financial support from AstraZeneca, Bristol-Myers-Squibb, MSD, Roche. DG, consultation fees from Transgene SA. AG, OG, FG, AS, AK, MD, DD, MN, AL, EA, VL declare that they have no competing interests.